Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00577-7/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=lancetcovid22&utm_medium=email&_hsmi=286691763&_hsenc=p2ANqtz-88WGnDTCW9IppfVzCbg7tsE5k9RZ4E11mG4Y1XGnz0RGw-eww9pkFnq3J7sVVMDa_gXWtSB1XoVOlL3O9w6Y6JLqtERw&utm_content=286678291&utm_source=hs_email